Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JAK1 Inhibition in Granuloma Annulare: an Opportunity for Pathogenesis Directed Therapy

NCT05650736 is registered in ClinicalTrials.gov with William Damsky as lead sponsor.

NCT NCT05650736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05650736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JAK1 Inhibition in Granuloma Annulare: an Opportunity for Pathogenesis Directed Therapy
Lead sponsor
William Damsky
Phase
Phase 2
Overall status
Completed
Start date
October 27, 2023
Completion date
May 7, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

granuloma annulare